Consistent with this report, Nagahara et al. (13) showed that, in Meth-A tumor-bearing mice, Gal-9 increased the number of Tim-3+ CD86+ mature DCs in vivo and prolonged survival, and that depletion of Tim-3+ DCs from Gal-9-treated tumor-bearing mice decreased anti-tumor immunity, indicating that Tim-3 expression on DCs plays a critical role in Gal-9-promoted anti-tumor immunity. Here, HAVCR2 is linked to neoplasm.